WG
GALT icon

Winton Group’s Galectin Therapeutics GALT Stock Holding History

Winton Group’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-30,196
Closed -$111K – 1628
2019
Q3 		$111K Sell
30,196
-10,083
-25% -$36.4K ﹤0.01% 1454
2019
Q2 		$167K Buy
40,279
+10,986
+38% +$47.6K ﹤0.01% 1048
2019
Q1 		$150K Buy
+29,293
New +$141K ﹤0.01% 995

Other funds holding GALT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return
AG
Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Winton Group's GALT Position: Q4 2019 in Review

Winton Group sold out of Galectin Therapeutics (GALT) in Q4 2019, closing a stake of 30,196 shares — an estimated $111K sold.

Winton Group first reported a position in GALT in Q1 2019 and held it in 3 quarters. The position peaked at $167K in Q2 2019. 78 funds tracked by Wall St. Rank hold GALT as of Q4 2019.

  • Winton Group reported no remaining Galectin Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Winton Group sold 30,196 Galectin Therapeutics shares in Q4 2019, an estimated $111K.
  • Winton Group first reported a position in Galectin Therapeutics in Q1 2019 and held it in 3 quarters.
  • Winton Group's Galectin Therapeutics position peaked at $167K in Q2 2019.
  • 78 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q4 2019.

Based on Winton Group's 13F filing for Q4 2019, filed 13 Feb 2020.